• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Fibrinolysis for pulmonary embolism may prevent hemodynamic collapse [PEITHO trial]

byTomi Jun
April 10, 2014
in Chronic Disease, Emergency, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: CC/Heilman

1. Fibrinolysis in addition to standard anticoagulation reduced hemodynamic decompensation, but did not affect overall mortality, in patients with intermediate-risk pulmonary embolism.  

2. Fibrinolysis was associated with greater risk of bleeding and stroke. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: A pulmonary embolism (PE) that causes persistent hypotension is considered a massive PE. Those that do not meet this criterion are considered submassive. At present, fibrinolytic therapy is only indicated for massive PE. This trial investigates whether fibrinolytic therapy is appropriate for cases of submassive PE where there is evidence of right ventricular dysfunction and myocardial injury – what the authors call intermediate-risk pulmonary embolism. Fibrinolysis in this setting has been a controversial subject and this is the largest trial to address this question thus far.

The primary outcome in this trial was a composite of hemodynamic decompensation and death from any cause within 7 days of randomization. The results show that fibrinolysis in addition to standard anticoagulation reduced the primary outcome by about 50%. However, fibrinolysis primarily reduced the incidence of hemodynamic decompensation. There was no difference in overall mortality between the two groups either at 7 or 30 days. Death was an infrequent event in both groups, suggesting that the placebo group strategy of standard anticoagulation followed by fibrinolysis in the event of hemodynamic collapse could be a valid approach to management of these patients. Fibrinolysis was associated with a significant increase in the incidence of major extracranial bleeding and stroke.

Click to read the study, published today in NEJM

RELATED REPORTS

Venous thromboembolism rates in hospitalized children continue to rise

Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

The use of a diagnostic strategy with age-adjusted D-dimer thresholds was non-inferior in risk-stratifying for thromboembolic events in emergency department patients with suspected pulmonary embolism

Click to read the accompanying editorial in the NEJM

Relevant Reading: Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review

In-Depth [randomized controlled trial]: A total of 1006 patients from multiple countries were randomized to standard anticoagulation with heparin plus a one-time bolus of either the fibrinolytic, tenecteplase or a bolus of placebo. These were patients with intermediate-risk PE based on CT and/or echocardiography findings consistent with right ventricular dysfunction, plus evidence of myocardial injury confirmed by increased troponin levels.

The primary composite outcome of hemodynamic deterioration or death within 7 days was significantly lower in the fibrinolysis group (2.6% vs. 5.6%, P=0.02). Death within 7 days was not significantly different between the two groups (1.2% vs. 1.8%, P=0.42). There was a lower incidence of hemodynamic decompensation in the fibrinolysis group (1.6% vs. 5.0%, P=0.002).

There was a significantly higher incidence of bleeding and stroke in the fibrinolysis group in the first 7 days: major extracranial bleeding (6.3% vs. 1.2%, P<0.001); minor bleeding (32.6% vs. 8.6%); major bleeding (11.5% vs. 2.4%); stroke (2.4% vs. 0.2%, P=0.003). There was a similar incidence of serious adverse events within the first 30 days after randomization (10.9% vs. 11.8%, P=0.63).

More from this author: Early risk factor for progression of cystic fibrosis identified, Gut microbes implicated in stroke and heart attacks: new dietary link, New leukemia mutation offers therapeutic targets, Childhood ADHD associated with increased risk of suicide, A marker of aggressive liver cancer and potential therapeutic target identified 

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: fibrinolysispulmonary embolism
Previous Post

Spironolactone not beneficial in heart failure with preserved ejection fraction [TOPCAT trial]

Next Post

Colorectal cancer resection associated with more complications in elderly

RelatedReports

siRNA against antithrombin alleviates symptoms of hemophilia [PreClinical]
Chronic Disease

Venous thromboembolism rates in hospitalized children continue to rise

February 14, 2022
Most anticoagulants for venous thromboembolism similarly effective
Hematology

Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

January 18, 2022
Quick Take: Hospital volume and outcomes for acute pulmonary embolism
Emergency

The use of a diagnostic strategy with age-adjusted D-dimer thresholds was non-inferior in risk-stratifying for thromboembolic events in emergency department patients with suspected pulmonary embolism

December 10, 2021
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Emergency

Utility of D-dimer testing and modified thresholds for ruling out pulmonary embolism in COVID-19 patients

October 13, 2021
Next Post
RAS mutation linked with survival in metastatic colorectal cancer

Colorectal cancer resection associated with more complications in elderly

HLA-DRB1*07:01 confirmed as risk factor for lapatinib-induced liver damage

Cetuximab and neoadjuvant chemotherapy may decrease survival in liver metastasis

Exemestane for breast cancer prevention has little effect on quality of life

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events
  • Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia
  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.